Home › Compare › MCKRF vs MRK

MCKRF vs MRK: Dividend Comparison 2026

MCKRF yields 90909.09% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCKRF wins by $1.8657767678438335e+26M in total portfolio value
10 years
MCKRF
MCKRF
● Live price
90909.09%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8657767678438335e+26M
Annual income
$186,174,819,330,989,220,000,000,000,000,000.00
Full MCKRF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — MCKRF vs MRK

📍 MCKRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCKRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCKRF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MCKRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCKRF
Annual income on $10K today (after 15% tax)
$7,727,272.73/yr
After 10yr DRIP, annual income (after tax)
$158,248,596,431,340,840,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MCKRF beats the other by $158,248,596,431,340,840,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCKRF + MRK for your $10,000?

MCKRF: 50%MRK: 50%
100% MRK50/50100% MCKRF
Portfolio after 10yr
$9.328883839219167e+25M
Annual income
$93,087,409,665,494,610,000,000,000,000,000.00/yr
Blended yield
99.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MCKRF
No analyst data
Altman Z
-17.2
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCKRF buys
0
MRK buys
0
No recent congressional trades found for MCKRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCKRFMRK
Forward yield90909.09% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$1.8657767678438335e+26M$30.7K ✓
Annual income after 10y$186,174,819,330,989,220,000,000,000,000,000.00 ✓$950.29
Total dividends collected$1.865512718252454e+26M$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MCKRF vs MRK ($10,000, DRIP)

YearMCKRF PortfolioMCKRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$9,101,609$9,090,909.09$11,192$351.54+$9.09M → MCKRF
2$7,742,626,649$7,732,887,927.71$12,524$392.70+$7742.61M → MCKRF
3$6,156,202,768,855$6,147,918,158,340.57$14,015$438.65+$6156202.75M → MCKRF
4$4,575,037,364,168,400$4,568,450,227,205,725.00$15,682$489.96+$4575037364.15M → MCKRF
5$3,177,871,744,582,025,000$3,172,976,454,602,365,000.00$17,547$547.23+$3177871744582.01M → MCKRF
6$2,063,199,081,001,827,700,000$2,059,798,758,235,125,000,000.00$19,632$611.16+$2063199081001827.75M → MCKRF
7$1,252,022,771,935,710,300,000,000$1,249,815,148,919,038,400,000,000.00$21,963$682.53+$1252022771935710208.00M → MCKRF
8$710,154,989,871,965,200,000,000,000$708,815,325,505,994,000,000,000,000.00$24,571$762.18+$710154989871965274112.00M → MCKRF
9$376,502,292,891,686,800,000,000,000,000$375,742,427,052,523,800,000,000,000,000.00$27,486$851.08+$3.7650229289168676e+23M → MCKRF
10$186,577,676,784,383,340,000,000,000,000,000$186,174,819,330,989,220,000,000,000,000,000.00$30,745$950.29+$1.8657767678438335e+26M → MCKRF

MCKRF vs MRK: Complete Analysis 2026

MCKRF — Stock

Jade Leader Corp. engages in the exploration and development of mineral properties in Canada and the United States. The company primarily explores for gold, copper, nickel, zinc, nephrite jade, and silver deposits. It holds a 100% interest in the Tell property that consists of 193 claims covering an area of 4,000 hectares located to the east of Mayo, Yukon; the DJ Jade project consisting 18 lode claims, which covers an area of approximately 140 hectares located in Washington State; and the Wyoming Jade Fields that consists of 99 mineral lode claims covering an area of 1,800 acres located in Wyoming. The company is headquartered in Calgary, Canada.

Full MCKRF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this MCKRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCKRF vs SCHDMCKRF vs JEPIMCKRF vs OMCKRF vs KOMCKRF vs MAINMCKRF vs JNJMCKRF vs ABBVMCKRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.